Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Sirolimus in High Risk MDS or Refractory AML
NCT01869114Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2013
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2013; status: completed.
02
Drugs
sirolimus
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01869114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01869114.